US 9,808,018 B2
Alpha-amylase variants
Rene Marcel De Jong, Echt (NL); Hanna Elisabet Abbas, Echt (NL); and Evert Tjeerd Van Rij, Echt (NL)
Assigned to DSM IP ASSETS B.V., Heerlen (NL)
Appl. No. 14/767,406
Filed by DSM IP ASSETS B.V., Heerlen (NL)
PCT Filed Feb. 27, 2014, PCT No. PCT/EP2014/053853
§ 371(c)(1), (2) Date Aug. 12, 2015,
PCT Pub. No. WO2014/131842, PCT Pub. Date Sep. 4, 2014.
Application 14/767,406 is a continuation of application No. 13/842,344, filed on Mar. 15, 2013, granted, now 9,301,533.
Claims priority of provisional application 61/771,676, filed on Mar. 1, 2013.
Claims priority of application No. 13157398 (EP), filed on Mar. 1, 2013; and application No. 13183144 (EP), filed on Sep. 5, 2013.
Prior Publication US 2015/0376588 A1, Dec. 31, 2015
Int. Cl. C12N 9/28 (2006.01); A21D 8/04 (2006.01)
CPC A21D 8/042 (2013.01) [C12N 9/2417 (2013.01); C12Y 302/01001 (2013.01)] 18 Claims
 
1. A variant polypeptide having alpha-amylase activity, wherein the variant has an amino acid sequence which, when aligned with the alpha-amylase comprising the sequence set out in SEQ ID NO: 2, comprises at least one substitution of an amino acid residue corresponding to any of amino acids
16, 45, 72, 77, 94, 134, 174, 177, 178, 186, 210, 234, 283, 284, 323, 325, 652,
said positions being defined with reference to SEQ ID NO: 2 wherein the alpha-amylase polypeptide variant is at least 90% identical to SEQ ID NO: 2, and wherein the variant has one or more altered properties as compared with a reference polypeptide having alpha-amylase activity, wherein the at least one altered property is an increased sucrose tolerance.